

**POSTER PRESENTATION**

**Open Access**

# IL15N72D superagonist/IL15R $\alpha$ -Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model

Peter S Kim<sup>1\*</sup>, Anna R Kwilas<sup>1</sup>, Emily K Jeng<sup>2</sup>, Hing C Wong<sup>2</sup>, Jeffrey Schlom<sup>1</sup>, James W Hodge<sup>1</sup>

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

National Harbor, MD, USA. 4-8 November 2015

Interleukin (IL)-15N72D-superagonist-complexed with IL15R $\alpha$ -Fc fusion protein (IL15-SA/IL15R $\alpha$ -Fc, also known as ALT-803) has been reported to have greater anti-myeloma activity, due to its increased *in vivo* half-life and unique tissue biodistribution, than native IL-15 alone in murine models. In order to test the anti-tumor efficacy of IL15-SA/IL15R $\alpha$ -Fc in a non-hematologic murine cancer model, we examined the monotherapy effect of IL15-SA/IL15R $\alpha$ -Fc in non-tumor bearing mice and in the 4T1-breast tumor model. In non-tumor bearing Balb/c mice, IL15-SA/IL15R $\alpha$ -Fc (1  $\mu$ g i.p.), a 10-fold increase occurred in NK cells followed by CD8<sup>+</sup> T cells (3-fold), both peaking on Day 3 post treatment. In examining NK cell population subsets, the greatest significant change was in high effector (CD11b<sup>+</sup>, CD27<sup>hi</sup>) NKs as compared with terminal effector (CD11b<sup>+</sup>, CD27<sup>lo</sup>) NKs on Day 3 post IL15-SA/IL15R $\alpha$ -Fc-treatment, leading to increased NK function on a per-cell basis. CD8 subset analysis determined that IL15-SA/IL15R $\alpha$ -Fc significantly increased IL15-responding, memory (CD122<sup>+</sup>, CD44<sup>+</sup>) CD8<sup>+</sup> T cells, in particular those having the innate (NKG2D<sup>+</sup>, PD1<sup>-</sup>) phenotype. In 4T1 tumor bearing mice, IL15-SA/IL15R $\alpha$ -Fc induced significant anti-metastatic activity, and thus consequently resulted in a longer median survival of IL15-SA/IL15R $\alpha$ -Fc-treated mice following surgical resection of the primary tumor. Finally, T cell depletion revealed that the anti-metastatic property of IL15-SA/IL15R $\alpha$ -Fc was dependent on CD8<sup>+</sup> T cells and not CD4<sup>+</sup> T cells. Altogether, these studies showed for the first time that IL15-SA/IL15R $\alpha$ -Fc a) promoted the development of high effector NKs, b) enhanced per-cell function of NKs,

and c) played a vital role in reducing tumor metastasis and ultimately survival.

#### Authors' details

<sup>1</sup>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

<sup>2</sup>Altor BioScience Corporation, Miramar, FL, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P229

**Cite this article as:** Kim et al.: IL15N72D superagonist/IL15R $\alpha$ -Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P229.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA  
Full list of author information is available at the end of the article